Sarah Lawrence College

DigitalCommons@SarahLawrence
Human Genetics Theses

The Joan H. Marks Graduate Program in
Human Genetics

5-2020

The Efficacy of Whole-Genome Sequencing in the Diagnosis Of
Complex Neurological Phenotypes
Bianca Blake
Sarah Lawrence College

Follow this and additional works at: https://digitalcommons.slc.edu/genetics_etd
Part of the Genetics and Genomics Commons

Recommended Citation
Blake, Bianca, "The Efficacy of Whole-Genome Sequencing in the Diagnosis Of Complex Neurological
Phenotypes" (2020). Human Genetics Theses. 80.
https://digitalcommons.slc.edu/genetics_etd/80

This Thesis - Open Access is brought to you for free and open access by the The Joan H. Marks Graduate Program
in Human Genetics at DigitalCommons@SarahLawrence. It has been accepted for inclusion in Human Genetics
Theses by an authorized administrator of DigitalCommons@SarahLawrence. For more information, please contact
alester@sarahlawrence.edu.

THE EFFICACY OF WHOLE-GENOME SEQUENCING IN THE
DIAGNOSIS OF COMPLEX NEUROLOGICAL PHENOTYPES
Bianca Blake
May 2020

Submitted in partial fulfillment
of the requirements for the degree of
Master of Science in Human Genetics
Sarah Lawrence College

ABSTRACT
Whole-genome sequencing (WGS) is being increasingly utilized for the diagnosis of
neurological disease. The advent of next-generation sequencing (NGS) has replaced Sanger
sequencing due to its ability to sequence millions of fragments in parallel, in real-time. It’s
application in targeted gene panels and whole-exome sequencing (WES) has revolutionized
standard investigation practices of neurodevelopmental diseases (NDDs). WGS utilizes NGS
technology in order to sequence beyond the exome and into the remaining 98-99% of the genetic
code comprising the genome. In addition to increased coverage, WGS allows for the detection of
novel gene variants, copy number variants (CNVs) and single nucleotide variants (SNVs) that
are not traditionally picked up by WES. Furthermore, RNA sequencing (RNA-Seq) of the blood
used in conjunction with WGS may have the ability to validate WGS findings by analyzing gene
expression in addition to identifying novel RNA species within the transcriptome. The objective
of this retrospective study was to measure the diagnostic yield of trio-based WGS and RNA-Seq
against that of negative or inconclusive WES in a patient cohort comprised of complex
neurological phenotypes. Whole genome sequencing was performed by Medical Neurogenetics
LLC, a CLIA-certified laboratory in Atlanta, Georgia. This laboratory utilized the Illumina
NovaSeq 6000 Sequencing System, with a goal of 30x coverage of 99% of mapped genome
regions. Alignment and variant interpretation was performed by Dragen v2.2 and CNV analysis
by Dragen v2.5. Variants were assessed in accordance with current ACMG criteria. WGS with
complementary RNA-Seq resulted in 7 solved patient cases, providing a 31.8% yield. This
phenotypically complex cohort was comprised of a spectrum of neurological conditions with
suspected underlying genetic mechanisms. The use of WGS in conjunction with RNA-Seq
resulted in a markedly increased diagnostic yield over that of preceding WES and conventional
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first-tier tests which included chromosomal microarray, targeted gene panels, and metabolic
testing. Thus, proving its efficacy in the clinical setting.
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INTRODUCTION
Technological advances in genetic sequencing over the last decade have had considerable
impact on genetic testing in both clinical and research settings. Next generation sequencing
(NGS) has consequently replaced Sanger sequencing when testing for phenotypically variable
syndromes due to its ability to sequence large numbers of genes simultaneously at a reduced
cost. This has led to NGS being applied to targeted enrichment methods in addition to wholeexome sequencing (WES) and whole-genome sequencing (WGS) techniques (Petersen et al.,
2017). The high resolution of NGS technology utilized in modern-day gene sequencing has
allowed for the accelerated discovery of neurodevelopmental disease (NDD) associated genes
(Srivastava et al., 2019).
There is a high level of complexity with respect to the evaluation of NDDs and the
introduction of WGS to current first-tier standard diagnostic testing technologies. Current
workup of NDDs in the clinical setting include chromosomal microarray analysis (CMA),
karyotype, MRI and/or ultrasound imaging, Fragile X syndrome (FXS) testing, metabolic testing,
and mitochondrial DNA (mtDNA) sequencing (Srivastava et al., 2019). In addition to these firsttier tests, WES has also been applied in clinical settings due to its significantly higher diagnostic
yield in comparison to that of CMA.
A molecular diagnosis is important for patients living with NDDs and their families as it may
impact clinical management (Srivastava et al., 2019). Introducing trio-based WGS subsequent to
current first-tier tests with inconclusive WES, increases diagnostic yield due in part to its
increased genomic coverage and ability to capture copy number variants (CNVs) and single
nucleotide variants (SNVs). By applying a trio-based approach, novel variants can be ruled in or
out during variant analysis and interpretation processes.
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Whole-Genome Sequencing vs. Whole-Exome Sequencing
The exome encompasses approximately 95% of the protein-coding regions of the genome
and comprises approximately 20, 000 genes, while accounting for just 1-2% of the genome itself
(Alfares et al., 2018). It is thought that approximately 85% of the pathogenic variants responsible
for Mendelian conditions occur in these protein-coding regions of the genetic code or within
canonical splice sites (Majewski et al., 2011). Genetic variants associated with complex traits,
such as those associated with NDDs, may occur outside of these protein-coding sequences.
These genetic variations arise within the remainder of the genome and may affect regulatory
elements required for gene expression such as promoter regions, enhancer regions, and silencer
sequences (Dinger et al., 2018). Due to WGS’ ability to reach beyond the exome and capture the
intronic regions not picked up by WES, it is currently considered the most comprehensive
genetic test available (Gilissen at al., 2014).
Moreover, it appears that WGS provides better coverage of exons and is less susceptible
than WES to distortions and blind spots in addition to being better able to detect copy CNVs and
complex genomic rearrangements, such as inversions (Mattick et al., 2018). In addition, WGS is
less sensitive to GC content, increasing its likelihood of providing complete coverage within GCrich regions (Odgerel et al., 2019). WGS has facilitated the discovery of novel pathogenic
variants in addition to the CNVs, genomic rearrangements, and SNVs that have been strongly
associated with Mendelian conditions that are not picked up by traditional WES (Srivastava et
al., 2019).
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The Benefit of RNA-Sequencing Analysis
In addition to WGS, other multi-omic technologies such as epigenomics, lipidomics,
metabolomics, and transcriptomics are sometimes being used as diagnostic tools for clinical
cases. Evaluation of the transcriptome by RNA-Seq provides the benefit of analyzing the RNA
by looking at alternative gene spliced transcripts, post transcriptional modifications, gene
fusions, SNVs, changes in gene expression over time and differences in gene expression among
different tissues. When used in conjunction with WGS, assays which assess the impact of
variants at the mRNA level, such as RNA-Seq, prove beneficial in evaluating the outcomes of
variants within deep intronic regions, splice junctions, and untranslated regions (Richards et al.,
2015). Identifying genomic variation is important for establishing a relationship between
genotype and phenotype and provides further insight into human disease (Piskol, Ramaswami, &
Li., 2013).

Whole-Genome Sequencing Limitations
Currently, a key limitation of WGS as a first-tier diagnostic test in the clinical setting is
cost. The cost of the sequencing technology in addition to the cost of labour required during the
interpretation process and the disclosure of results is a significant obstacle. WGS will likely
become more widely used in the future as the cost decreases over time. Furthermore, ACMG
guidelines are insufficient for the classification of deep intronic variants that can be detected by
WGS (Richards et al., 2015). The current guidelines consist of a 5-tiered system of classification
relevant for variants within genes responsible for Mendelian disease, majority of which are
exonic.
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Study Objectives
This retrospective study reports on the diagnostic yield of trio-based WGS with RNA-Seq
in a cohort of patients who had initially been referred for evaluation of a complex neurological
phenotype suspicious for an underlying genetic condition. All probands had negative or
inconclusive WES results within the antecedent five years. The objective was to assess the
diagnostic value of WGS and RNA-Seq after a negative or inconclusive WES result.
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MATERIALS & METHODS
Whole Genome Sequencing was performed by CLIA-certified laboratory Medical
Neurogenetics, LLC in Atlanta, Georgia (CLIA ID# 11D0703390; George Lab Lic. Code 060381). Sequencing was performed by Illumina NovaSeq 6000 with a goal of 30x coverage of over
99% of uniquely mappable regions of the genome.. Alignment and variant interpretation (SNV
and CNV) was performed by Dragen v2.6. Variants were assessed according to ACMG criteria
(Richards et al., 2015). Sequencing of the mitochondrial genome was performed on an Illumina
NovaSeq with a goal of >500-fold average coverage. Repeat expansions for ATN1, ATXN1,
ATXN2, ATXN3, ATXN7, ATXN8, ATXN10, C9ORF72, TBP, and ZNF9 was assessed with
ExpansionHunter version v2.5.5 and findings confirmed by repeat-primed polymerase chain
reaction (Dolzhenko et al., 2017).
In addition to WGS sequencing, RNA sequencing was also performed by Medical
Neurogenetics. Next generation sequencing (NGS) libraries were created using the TruSeq
Stranded Total RNA library (Illumina) kit. Sequencing was also performed on an Illumina
NovaSeq 6000 instrument with a targeted sequencing yield of 22 giga base pairs (Gbp). RNA
secondary analysis was performed following the Nature protocol, “Transcript-level expression
analysis of RNA-seq experiments with HISAT, StringTie and Ballgown”. Additional RNA-seq
analysis was performed using in-house developed analysis for differential expression and small
variant calling by GATK HaplotypeCaller v4.1.2.0.
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Demographic Data
The patient cohort consisted of 22 patients from 20 families who had initially been
referred for evaluation of a complex neurological phenotype suspicious for an underlying genetic
condition. The participants in this study were assessed in a pediatric and adult
neuromuscular/neurogenetics clinic in Hamilton ON, Canada. The patient cohort was diverse
with respect to ethnicity, age at first presentation, and age at which they underwent WGS
(current median age: 20 y, current age range: 4 – 49 y). All cases had negative or indeterminate
WES results within the antecedent five years. Detailed clinical summaries are available for each
patient in the supplemental files.

Solved vs. Unsolved Cases
For the purpose of this study we define a case as “solved” when the variant interpretation
and analysis reveals a molecular explanation of the patient phenotype regardless of the WGS
outcome. We have provided corresponding numbers from the Online Mendelian Inheritance in
Man (OMIM) database for the phenotypes described during case analyses.
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RESULTS
In total, each of the 22 patients enrolled in the study had a complete clinical and final
result available from WGS. Of these, 3 (13.6%) had positive WGS results, 16 (72.7%) had
indeterminate results, and the 3 (13.6%) remaining patients had negative WGS results. When
analyzed in conjunction with RNA-Seq results, we received a combined total of 7 (31.8%)
solved patient cases (Table 1). WGS results are current as of 2019, reanalysis has not yet been
performed. The option of learning ACMG actionable secondary findings was given to each
patient/family.
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Table 1. Summary of WES, WGS, and RNA-Seq results for all 20 participants

VUS

VUS

Negative

Negative

Negative

Unsolved

Unsolved

Unsolved

Unsolved

WGS Results

undetermined

Negative

WES Results

mat

VUS

Unsolved

Outcome

p.Ala 955Thr

VUS

Negative

Unsolved

Variant
RNA-Seq
Classification Results

p.Thr77Ile

mat

VUS

Negative

Origin

c. 2863G>A

pat

VUS

Amnio Acid
Change
Negative

c.230C>T

p.Glu306Lys

pat

VUS

Nucleotide
Change

SHANK3

p.Thr410Met

mat

Gene

REFLN

c.916G>A

p. Asp389Asn

pat

Variant
Family
Classification

Gene

Trio

Negative

c.1229C>T

p.Val147Leu

Origin

Family

Duo

ENTPD5

c.1165G>A

p.Met988Thr

Amnio Acid
Change

Clinical Description

Negative

Trio

ENTPD5

c.439G>C

Nucleotide
Change

Sex

Trio

Trio

MYO1A

c.2963T>C

Patient
Number
F

Negative

VUS

IDH2

1

Non-verbal, global developmental
delay, seizures, hand flapping/hand
obsession, complex I deficiency,
slightly underdeveloped corpus
callosum and decreased volume of
white matter

Duo

pat

Trio

MYH2

F

2

p.Leu511Pro

VUS

Quad

Neurodegenerative disorder with
progressive ataxia, spasticity,
seizures, cerebellar atrophy, and
retinitis pigmentosa

Negative

c.1532T>C

pat

VUS

M

3

SDHA

p. Asp389Asn

VUS

Non-verbal, intellectual disability,
Trio
macrocephaly, periventricular white
matter changes, cyanotic seizure-like
episodes

Trio

c.1165G>A

mat

VUS

F

4

MYO1A

pat

Neurodegenerative disorder with
regression at 12 months, epilepsy,
ataxia, spasticity, non-verbal, brain
biopsy suggestive of a necrotizing
encephalopathy

Trio

p.Val147Leu

mat

M

5

c.439G>C

p.Met988Thr

Slowly neurodegenerative disorder
with cognitive decline, retinitis
pigmentosa, scoliosis, cerebellar
atrophy, bilateral sensorineural
hearing loss, generalized weakness
and muscle atrophy, ataxia, and
contractures

IDH2

p.Ala489Thr

M

c.2963T>C

6a

c.1465G>A

Dizygotic twin brothers with epilepsy, Quad
severe intellectual disability,
choreoathetotic movements, and
spasticity

MYH2

M

PXK

6b

Notes: All variants are heterozygous unless otherwise specified. VUS: variant of uncertain significance, LP: likely pathogenic, P: pathogenic
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Gene

c.1052C>T

c.2276G>T

Nucleotide
Change

p.Gly309Ter

p.Arg818His

p.Ser351Leu

p.Cys759Phe

Amnio Acid
Change

mat

mat

mat

mat

Origin

VUS

VUS

LP

P

Variant
Family
Classification

Table 1 (continued).

USH2A

c.2453G>A

WGS Results

Clinical Description

PANK2

c.925G>T

WES Results

Sex

WFS1

Family

Patient
Number
F

ACBD5

Gene

Nucleotide
Change

p.Gly309Ter

Amnio Acid
Change

pat

mat

Origin

P

LP

Variant
RNA-Seq
Classification Results

Outcome

Solved - ACBD5

c.925G>T

Negative

ACBD5

Exon 4 deletion (Chr10:27,510,50127,513,251 (GRCh37))

Unsolved

ACBD5

Negative

Negative

Solved - EXOSC8

Trio

Trio

7

Atypical neurodegeneration with
Trio
brain iron accumulation (NBIA),
progressive cognitive decline, ataxia,
rigidity/spasticity, spastic bladder, and
retinal detachment with retinitis
pigementosa

Negative

Negative

c.318delG

LP

APOA1BP

p.Ser107Alafs*49 mat

Trio

c.98G>A (homo) p.Arg33Lys

VUS

VUS

Exon 3 deletion (Chr8:108,066,751108, 095, 501 (GRCh37)) (homo)

undetermined

VUS

mat + pat

EXOSC8

p.Tyr951Ser

mat

VUS

Trio

F

Progressive weakness, ataxia, optic
atrophy, omnidirectional nystagmus,
spasticity, peripheral neuropathy,
complex I+III deficiency, and 3methylglutaconic aciduria
PLEKHG5

9

8

F

Moderate intellectual disability,
Trio
ataxia, pure motor
neuropathy/neuronopathy, dysarthria,
CoQ10 deficiency in muscle

p.Pro743Leu

mat

Solved - SLC44A1

SLC44A1

c.2852A>C

p.Pro2490His

undetermined

Negative

Quad

POLG

c.2228C>T

p.His2754Tyr

P

Negative

Duo

c.7469C>A

p.Arg486His

mat + pat

Duo

LP

DNM2

c.8260C>T

VUS

F

Intellectual disability, progressive
ataxia, scanning speech, vision loss,
spasticity, dysarthria, dysphagia,
bowel and bladder incontinence, and
mild proximal weakness

undetermined

ZNF469

c.1457G>A

pat

10a

M

p.Tyr951Ser

VUS

ZNF469

Solved - POLG

c.2852A>C

mat

VUS

EPHA2

Negative

POLG

p.Pro743Leu

VUS

LP

Duo

c.2228C>T

p.Pro2490His

mat

TSEN54

c.1168G>A

c.919G>T

p.Gly390Arg

p.Ala307Ser

pat

pat

P

P

VUS

DNM2

c.7469C>A

p.His2754Tyr

ASS1

undetermined

ZNF469

c.8260C>T

P

undetermined
ZNF469

pat

Unsolved

p.Ala307Ser

Negative

c.919G>T

Trio

TSEN54

Trio

p.Gly899Ser

10b

M

Severe distal axonal peripheral
neuropathy, progressive dysphagia,
global developmental delay,
congenital cataracts, glaucoma,
corneal dystrophy, nystagmus, and
retinal detachment

12

c.2695G>A

11

F

Focal epilepsy, global developmental
delay, microcephaly, hypotonia,
hypermobility, tent-shaped mouth

Notes: All variants are heterozygous unless otherwise specified. VUS: variant of uncertain significance, LP: likely pathogenic, P: pathogenic
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Table 1 (continued).

Nucleotide
Change

Amnio Acid
Change

Origin

Variant
Family
Classification

Gene

Nucleotide
Change

Amnio Acid
Change

pat

Origin

VUS

Pathogenic

Variant
RNA-Seq
Classification Results

WGS Results

Gene

p.Asn238Ser

WES Results

Family

c.713A>G

Clinical Description

RMND1

Sex

Pathogenic

Patient
Number
pat

Outcome

Unsolved

Unsolved

p.Asn238Ser

Negative

Negative

c.713A>G

Trio

RMND1

F

Trio

13

P

P

Unsolved

LP

Negative

de novo

VUS

pat

Unsolved

undetermined

p.His254Thrfs*2

Negative

p.Asn735Ser

p.Arg744Ter

VUS

c.2204A>G
(homo)

c.759dupA

VUS

SCN3A

c.2230C>T

mat

Duo

RMND1

p.Lys1860Thr

Unsolved

Abnormal exon splicing
Solved
of -ACAD9
ACAD9

Negative

Solved - SETX

SLC12A6

c.5579A>C

LP

Negative

RANBP2

c.859_862delinsC p.Phe287_Tyr288d pat
elinsHis

LP

LP

CHRNA2

p.Gln308Thr

pat

c.922C>T

Negative

KIAA0556

Duo

LP

VUS

mat

VUS

mat

de novo

pat

VUS

splice site variant mat + pat

LP

p.Gly204Cys

pat

p.Ala45Thr

pat

c.244+3A>G
(homo)

splice site variant mat

p.Thr8Met

p.Arg326Cys

mat

ACAD9

c.1441+2T>A

p.Val726Met

c.133G>A

p.Arg1962Cys

Trio

c.610G>T

c.23C>T

c.976C>T

p.Ile2892Ile

VUS

PNPT1

c.2176G>A

TKT

c.5884C>T

p.R150H

SLC39A8

SETX

Trio

c.8676C>T

p.P192S

Unsolved

IGHMBP2

Negative

VPS13A

c.449G>A

Negative

Trio

TKT

VUS

VUS

VUS

VUS

de novo

mat

pat

pat

p.Thr8Met

p.Ala45Thr

p.Val726Met

p.Arg326Cys

c.23C>T

c.133G>A

Negative

c.2176G>A

c.976C>T

SETX

TKT

Developmental regression, epileptic
encephalopathy, infantile
spasms/hypsarrythmia, LennoxGataut syndrome, severe global
developmental delay, microcephaly,
diffuse cerebellar atrophy

Trio

IGHMBP2

TKT

F

Intellectual disability and movement
disorder with myoclonus, dystonia,
chorea, supranuclear vertical gaze
palsy, and spasticity

Trio

14

Congenital hypomyelinating
neuropathy

F

VPS13A

c.574C>T

Trio

Moderate intellectual disability,
Trio
proximal weakness, spasticity, diffuse
cerebellar volume loss in the vermis,
poor balance

SLC25A10

VUS
SLC25A10

Negative

Trio

Spinocerebellar ataxia/ hereditary
spastic paraplegia overlap,
progressive cerebellar atrophy,
intellectual disability, nystagmus,
complex I+III deficiency

Negative

F

Cognitive decline, dysphagia,
Trio
neuropsychiatric features (mood and
personality changes, anxiety,
psychosis, aggression, hallucinations)

F

F

Spinocerebellar ataxia, optic atrophy, Singleton
intellectual disability, complex I
deficiency

Trio

F

Severe global developmental delay,
Trio
epilepsy, dysmorphic features,
hypertonia, hyperreflexia, cortical
visual impairment, cerebellar atrophy
and diffude volume loss on MRI

in trans

M

15

16

17

18

19

20

All variants are heterozygous unless otherwise specified. VUS: variant of uncertain significance, LP: likely pathogenic, P: pathogenic
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Figure 1. WGS Results
13.6%

13.6%

72.7%

Positive

Inderterminate

Negative

Notes: Chart of WGS results showing the proportion of patient cases that yielded a negative, positive,
or indeterminate result.

Figure 2. Diagnostic yield of WGS vs WES
25

22
20

15

15

Cases
Solved
Unsolved

10

7
5

0

0
WES

WGS

Notes: When analyzed in conjunction with RNA-Seq results, we received a combined total of 7 (31.8%)
solved patient cases (Table 1). WGS results are current as of 2019, reanalysis has not yet been performed.
The option of learning ACMG actionable secondary findings was given to each patient/family.
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DISCUSSION
In this study, WGS and RNA-Seq was performed for 22 patients with complex
neurological phenotypes and previous negative or indeterminate WES results. The goal was to
assess the diagnostic yield of WGS and RNA-Seq in patients with nondiagnostic WES results.
Many studies have been conducted to report the diagnostic yield of WGS as a first-line test
among a variety of conditions. In these study populations, the patients have either had no prior
genetic testing or have undergone an array of genetic testing including targeted gene sequencing,
sequencing panels, CMA, or WES. Our study differs as we are evaluating the diagnostic yield of
WGS in a population who homogenously had inconclusive or negative WES completed prior to.
At typical sequencing depth, WGS offers improved uniformity of exonic coverage
compared to that employed by WES, in addition to increased coverage and longer read lengths.
(Wilfert et al., 2017). Demonstrated in Supplemental Case 9, WGS (trio) identified homozygous
EXCOSC8 variants inherited maternally and paternally while WES (trio) in 2016 was negative.
The lower coverage exhibited by WES in comparison to WGS in that region resulted in the
variants being missed. The EXCOSC8 variants at c.98G>A (p.Arg33Lys) has been classified as
likely pathogenic, accurately representing the patients unexplained phenotype rendering the case
solved.
WGS has the ability to sequence beyond the protein-coding regions of the genome and
detect genomic variation outside of these regions, which play a role in the development of
complex traits and diseases (Alfares et al., 2018). WGS offers improved uniformity of exonic
coverage compared to that employed by WES when restricted to regions covered by both
platforms. For example, in gnomAD, 89.4% of the exome was covered by WES at 20x coverage
while WGS covered 97.1% at this same threshold.
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It is known that WGS allows for superior detection of copy number variations in known
disease genes over both WES and CMA. This includes de novo mutation (DNM) identification in
genes which were previously restricted to large CNVs. The identification of small deletions in
known/candidate disease genes led to a diagnosis in Case 7 and sibling Cases 10a/10b.
WES for siblings 10a and 10b (duo) was completed in 2015 and was negative. WGS
(quad) of the sibling pair in addition to each parent identified a homozygous deletion of exon 3
within SLC44A1 in both siblings. This deletion was predicted to result in a frameshift at amino
acid position 90 and the subsequent termination of 18 codons (Chapelle et al., 2019). SLC44A1
encodes for choline transporter-like protein 1, which has recently been associated with a
childhood-onset neurodegenerative condition with progressive ataxia, dysphagia, tremors,
cognitive decline, dysarthria, and optic atrophy (Fagerberg et al., 2020).
For Case 7, WGS was able to detect a deletion in exon 4 of ACBD5 which was not
identified by CMA or WES. The patient, a 29-year-old female, was known to have one
maternally inherited heterozygous variant of uncertain clinical significance in ACBD5
(c.925G>T, p.Gly309Ter). At the time WES was performed in 2015 ACBD5 was listed as a
candidate gene not yet associated with a human phenotype. WGS identified the maternally
inherited ACBD5 variant in addition to the novel discovery of the exon 4 deletion, which was of
paternal origin. RNA-Seq detected the deletion in ACBD5 in approximately 48% of reads
covering its position at c.935G>T (Table 1).
Additionally, RNA-Seq was proved an added benefit to WGS in this cohort and provided
a diagnosis for Case 20. WES for Case 20 was performed in 2017 and identified several variants
of interest, including a homozygous splice site variant of uncertain significance in ACAD9
(c.244+3A>G) and compound heterozygous variants (in trans) in candidate gene SLC25A10
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(c.G449A, p.R150H and c.C574T, p.P192S). The ACAD9 homozygous variants were not felt to
be diagnostic at the time because there was not a match with the described phenotype. The
classic phenotype of ACAD9-related mitochondrial complex I deficiency is muscle weakness,
hypotonia, cardiomyopathy, liver failure, encephalopathy, and Reye-like episodes in
infancy/childhood. The ACAD9 homozygous splice site variant was again identified by WGS
and RNA-Seq in blood confirmed that exon splicing was affected by this variant. Ataxia is still a
rarely reported phenotype of ACAD9-related mitochondrial complex I deficiency and it is likely
that this patient represents a milder phenotype of this condition.
In Cases 11 and 15, while unable to identify new variants or provide multi-omic support
to the pathogenicity of variants, WGS and RNA-Seq led to a final diagnosis by acting as a
reanalysis due to updated medical knowledge. Case 15 is a 9 year old male with congenital
hypomyelination syndrome. WES in 2014 identified a heterozygous de novo variant of uncertain
significance in SETX (c.23C>T, p.Thr8Met). Some heterozygous variants in SETX have been
associated with juvenile ALS type 4 (OMIM: 602433) while some biallelic variants have been
associated with ataxia-oculomotor apraxia type 2 (OMIM: 606002). The SETX (c.23C>T,
p.Thr8Met) variant has since been reclassified as “likely pathogenic” as we have been made
aware of a few other cases of children with the same de novo variant in SETX and identical
phenotype. Further work is being done to better characterize and publish this possible expansion
in phenotype.
Case 11 was known to have a likely de novo, likely pathogenic variant in POLG which
was felt to explain part of his phenotype. A recent publication by Castiglioni et al. in 2018
describes an expansion of the POLG phenotype which matches most of Case 11’s clinical
symptoms. WGS also identified biallelic variants of uncertain significance in ZNF469 potentially
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associated with Brittle cornea syndrome 1 (OMIM: 229200) and a heterozygous variant in
EPHA2 of unknown parental origin possibly associated with autosomal dominant cataracts type
6, multiple types (OMIM: 116600). It is presently unclear if these variants are playing any role in
the complex eye phenotype of this patient.
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CONCLUSION
In summary, WGS is revolutionizing the ability to diagnose complex neurological
phenotypes associated with NDDs in addition to acute monogenic disorders. With the ability of
WGS to poll more of the exome and reach the remaining 98-99% of the genetic code, WGS has
the ability to produce a higher diagnostic return. In our study, a 31.8% diagnostic yield is
reported by WGS subsequent to inconclusive or negative WES offered homogenously to this
patient cohort.
Other studies have reported the diagnostic yield of WGS to be as high as 21-34% in
individuals with broad spectrum disorders or congenital malformations and neurodevelopmental
disorders. These results parallel the results of our study. For example, Lionel et al. reported the
diagnostic yield of WGS to be as high as 41%, which was higher than that of WES by
approximately 26% (Lionel et al., 2018). It is worth mentioning that studies to support this claim
are few, and the patient population in this study did not homogenously undergo WES prior to
WGS. This emphasizes the need for additional studies directly comparing the diagnostic yield of
WGS when performed subsequent to indeterminate or negative WES among the same patient
population. In contrast to ours, a study by Alfares et al. found that prior to reanalysis, WGS
yielded a positive result in only 7% of their patient population subsequent to previously negative
WES results (Alfares et al., 2018).
In addition to being less susceptible to distortions, rearrangements, and blind spots, WGS
is also less sensitive to GC-rich content. With its additional ability to detect CNVs and SNVs,
WGS identifies novel variants that are not identified by conventional or WES. Ultimately, WGS
provides the complete dataset of an individual’s genetic composition.
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Current ACMG classification guidelines do not directly apply to variants identified
within deep intronic regions. This may be a contributing factor to the many variants resulting in
negative or indeterminate findings within our study. Providing additional sequencing of the RNA
transcriptome is becoming increasingly beneficial in establishing the significance of an
increasing amount of VUS results being yielded by WES and WGS. RNA sequencing has proven
useful in the identification of functional consequences of VUS results by providing examination
at the mRNA level. It has improved our ability to understand unknown variants by establishing
their effects within both regulatory regions and coding regions of the genome. It can be
integrated with WGS in order to interpret exonic and intronic SNVs and structural variants to
increase the diagnostic rate. To our knowledge, our study is one of few to integrate RNA-Seq of
the blood transcriptome into WGS in hopes of establishing increased diagnostic yield of complex
neurological phenotypes.
While our study focused on the benefits of NGS and diagnostic yield of WGS compared
to WES, there are some limitations worth noting. Phenotypes presented in our study consisted
only of complex neurological phenotypes, therefore, the results of our study may not be directly
applicable across specialties. There is a need for more research on the efficacy of WGS outside
of the neurologic setting.
A limitation to both WGS and WES is that a disease-causing variant may occasionally be
overlooked if it has not yet been identified as such. If a variant is not yet identified as causative
of a specific disease phenotype or the variant in question is within a gene of unknown function a
diagnosis may be missed. This addresses the need for increased variant reporting especially in
the case of extremely rare and phenotypically complex neurological diseases.
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In addition, our study employed a trio-based approach to facilitate comprehensive
interpretation of results, however, we did not address additional factors that may have influenced
the diagnostic yield of WGS. For example, it was not clearly stated for each patient the degree of
clinical involvement of a genetics team prior to their involvement with the neuromuscular clinic.
This includes unknown frequency of consults with a geneticist and whether or not they had
routine follow-ups with the genetics specialty prior to their involvement with our clinic. As a
result, this may have directly impacted the amount of time elapsed before further comprehensive
examination, testing and perhaps a diagnosis.
Analysis and discussion of secondary findings was beyond the scope of our study;
however, participants were informed of the possibility of secondary findings as per ACMG. The
option to report actionable secondary findings was provided to each patient case.
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APPENDIX
Appendix I: Clinical Case Summaries
Case 1
An 11-y-old girl first presented at 16 mo of age with global developmental delay,
hypotonia, bilateral ptosis, joint hypermobility, feeding difficulties, and failure to thrive (FTT).
She was born weighing 5 lbs 8 oz at 36 wk by C-section after an induced labour due to placental
abruption. At 20 mo of age she was not able to sit up on her own but could sit independently if
placed in that position. She was 3 y old when she had her first febrile seizure and 5 y old when
she had her first unprovoked generalized tonic-clonic seizure with loss of consciousness. At last
examination, she has profound intellectual disability, continues to have seizures, and is
nonverbal.
Karyotype analysis, array based comparative genomic hybridization (aCGH), CDKL5,
Angelman and Rett syndrome testing were negative. Lactate levels ranged from 1.1 to 2.3
nmol/L (N: 0.5 – 2.2 nmol/L) and she had a normal CK. Muscle ultrastructure pathology showed
a minimal amount of mitochondrial pleomorphism. Enzyme testing of skeletal muscle revealed a
mild complex I + III deficiency. NGS of mtDNA from skeletal muscle was negative for deletions
but revealed a homoplasmic variant in the MT-ND4 subunit (m.11240C>T; p.Leu161Phe). This
variant was also homoplasmic in her asymptomatic mother and was thus considered to likely be
benign.
WES (trio) performed in 2014 was negative. In 2019, the result of WGS (trio) was
negative. RNA-Seq of the entire fibroblast transcriptome did not identify any significant changes
in transcript levels or splicing patterns in genes believed to be related to the clinical presentation
of this patients.
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Case 2
This 33-y-old woman was born by uncomplicated delivery at term. She weighed 6 lb. 6
oz and her Apgar scores were within normal limits. She met all developmental milestones and
there were no concerns until around 10 y of age when it was noticed that she had reduced vision.
By 16 y of age she had been diagnosed with progressive visual loss due to retinitis pigmentosa.
She could no longer perceive light by 32 y of age.
At 17 y of age she started to show symptoms of progressive ataxia, also affecting speech.
She became pregnant at 23 y of age and gave birth to a male child. Her condition worsened after
birth with the commencement of seizures and severe and sharp headaches. By 30 y of age it
became clear that she had a progressive neurodegenerative disorder. She was displaying
abnormal behaviors and significant emotional outbursts with possible hallucinations and
decreasing cognition. Physical examination found progressive spasticity and ataxia. She passed
away at 33 y of age.
Initial investigations included a muscle biopsy which showed normal pathology and
muscle mitochondrial enzyme activities for complex I + III, IV and citrate synthase did not show
a significant deficiency. Multiple brain MRIs showed significant atrophy of the cerebellum and
vermis.
WES (trio) was performed in 2014 and was negative. WES re-analysis in 2016 was also
negative. WGS (duo) in 2018 identified two variants of uncertain significance. The two
heterozygous variants of uncertain significance were identified, one in each of the SHANK3 and
RELN genes. The SHANK3 (c.2863G>A; p.Ala955Thr) was of unknown parental origin and was
not identified in large databases. The RELN variant (c.230C>T; p.Thr77Ile) was inherited from a
clinically unaffected mother. RNA-Seq of the entire blood transcriptome did not identify any
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significant changes in transcript levels or splicing patterns in genes believed to be related to the
clinical presentation of this patient.
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Case 3
This 16-y-old boy who presented at 22 mo of age with global developmental delay,
macrocephaly (54 cm, >98th percentile), and periventricular white matter changes. He
experienced a seizure-like episodes once to twice a month with lip smacking, cyanosis of the
lips, and breath holding. These episodes were usually followed by vomiting. Evaluation by a
geneticist suggested a clinical diagnosis of MOMO Syndrome (Macrosomia, Obesity,
Macrocephaly, and Ocular Abnormalities – OMIM# 157980). He remains largely non-verbal.
Initial workup included mtDNA sequencing of blood and muscle tissue, genetic testing
for Prader-Willi syndrome, a genetic epilepsy panel, transferrin isoelectric focusing, microarray,
and metabolic screen. WES (trio) was performed in 2014 and was negative. WES re-analysis in
2016 was also negative. WGS (trio) was negative. RNA-Seq of the entire blood transcriptome
did not identify any significant changes in transcript levels or splicing patterns in genes believed
to be related to the clinical presentation of this patient.
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Case 4
This 11-y-old female had a neurodegenerative phenotype with epilepsy, global
developmental delays, and spasticity. Her development proceeded normally until ten mo of age
when a stagnation in development and a slightly broad-based gait with stiff legs was noted.
Regressions in her speech and motor skills became apparent at one year of age. Brain biopsy at
three y of age was suggestive of a necrotizing encephalopathy. Seizures began around four y of
age with a frequency of approximately five to eight per night. At five y of age she experienced
an additional regression of cognitive and motor skills. She became fully non-verbal and
experienced difficulties using her communication board. Due to increasing spasticity in her
lower limbs she required assistance with walking (braces and orthotics). By the age of seven y
her seizures occurred in clusters with a maximum of 25 within a timespan of 20 min each night.
Each cluster involved multiple episodes of posturing and stiffened leg or arm stretches followed
by post-ictal agitation. At age nine y of age she began having episodes of tonic stiffening during
the day. Brain MRI at three and a half years of age showed multifocal areas of acute ischemia in
the frontal lobes (bilateral), basal ganglia, and right cerebral peduncle. MR spectroscopy showed
a decrease of NAA in relation to creatine and a lactate peak. Serial MRIs over the next several
years showed continued slow progression.
Initial investigations included enzymatic testing of hexosaminidase, B-galactosidase, and
arylsulfatase. Genetic testing for Rett and Angelman syndrome, microarray, mtDNA sequencing
and mtDNA deletion/depletion analysis in muscle tissue, a leukodystrophy panel, and an
epilepsy panel were negative. Transferrin isoelectric focusing and immunoperoxidase for
parvoviruses were both negative. Muscle biopsy of the right vastus lateralis at three y of age
showed unremarkable pathology. Mitochondrial work up on fibroblasts, including analysis for
complex V deficiency and lactate to pyruvate ratio were negative.
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WES was done in 2014 and identified one paternally inherited heterozygous likely
pathogenic variant in SDHA (c.1532T>C; p.Leu511Pro). Biallelic pathogenic variants in SDHA
have been associated with autosomal recessive Leigh syndrome (OMIM: 600857).
Deletion/duplication analysis of the SDHA gene was normal and no second variant was
identified.
WGS (trio) was completed and identified compound heterozygous variants of uncertain
significance (in trans) in ENTPD5 (c.916G>A, p.Glu306Ly + c.1229C>T, p.Thr410Met). The
ENTPD5 gene encodes for an ectonucleoside triphosphate diphosphohydrolase but is currently a
candidate gene and does not have any definitive disease associations in humans. No gene or
phenotype matches were made through GeneMatcher (Sobreira et al., 2015). Transferrin
isoelectric focusing was unremarkable. RNA-Seq of the entire blood transcriptome did not
identify any significant changes in transcript levels or splicing patterns in genes believed to be
related to the clinical presentation of this patient.
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Case 5
A 25-y-old man was born at 42 week gestation with Apgar scores of 2 @ 1 min and 7 @
10 min and was diagnosed with cerebral palsy in and this diagnosis persisted for the first 17 y of
his life. He was first seen at 18 y of age with a complex phenotype of retinitis pigmentosa,
scoliosis, cerebellar atrophy/hypoplasia, bilateral sensorineural hearing loss (SNHL), progressive
generalized weakness, non-progressive ataxia, and significant contractures. During his most
recent evaluation he reported a decline in strength and overall function with progressive
cognitive decline and muscle atrophy.
Initial work-up included a normal; aCGH, skeletal muscle mtDNA sequencing, and
genetic testing for; Friedreich ataxia, POLG, FCMD, FKRP, POMgNT1, POMT1,and POMT2.
His CK was elevated at 901 iU/L (N: < 225 iU/L). Muscle biopsy of the right vastus lateralis
revealed extensive skeletal muscle atrophy with degeneration/necrosis, increased adipose tissue,
and nonspecific mitochondrial changes.
In 2014, WES (trio) identified one paternally inherited variant of uncertain significance
in MYO1A (c.1165G>A; p.Asp389Asn). Pathogenic variants in MYO1A can be associated with
an autosomal dominant nonsyndromic hearing loss (DFNA48) (OMIM: 607841) and the
proband’s father felt that he had some non-specific hearing loss, although this was not clinically
tested. In 2018, reanalysis of the WES results revealed no new findings. WGS (trio) identified
the same MYO1A VUS that was identified on WES, but no other findings. RNA-Seq of the entire
blood transcriptome did not identify any significant changes in transcript levels or splicing
patterns in genes believed to be related to the clinical presentation of this patient.
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Cases 6a and 6b
Case 6a is the 20-year-old male dizygotic twin of case 6b. He initially presented at 18 mo
of age with global developmental delay and a history of seizures. His first febrile seizure was
described as tonic-clonic and lasting approximately 30 seconds. Developmentally, he was able to
sit independently at 18 mo and walk with support. Neurological examination at 18 mo found lax
ankle joints, brisk symmetric reflexes, and macrocephaly (head circumference = 50.5 cm, >97th
percentile).
By three y of age he was experiencing myoclonic, convulsive, and focal seizures with left
sided stiffening and postictal shivering. He could crawl, walk with support, and feed himself
with his fingers. He had six to eight words in his vocabulary. At ~ 5 y of age he had a regression
while the frequency of seizures increased. At 16 y of age he displayed choreoathetosis and
quadriplegic cerebral palsy-like features along with profound intellectual disability. By 20 y old
he was having four to five generalized seizures per month, with a maximum seizure-free period
was one week.
Case 6b is the 20-year-old male dizygotic twin of case 6a. He presented with the same
phenotype of global developmental delay, hypotonia, and seizures occurring approximately 17
times a day. His head circumference was below the 90th percentile (49 cm). By 16 y he also had
choreoathetotic movements. Both brothers are non-verbal, and neither is currently able to walk
independently or feed themselves.
Diagnostic tests and investigations for the brothers included normal Initial investigations
included; cardiac echocardiography, EMG/NCS, brain MRI, and hearing exams. Vitamin E,
urine MPS and oligosaccharides, arylsulfatase, beta-hexosaminidase, beta-galactosidase,
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biotinidase, phytanic acid, serum acylcarnitine, and transferrin isoelectric focusing were
unremarkable.
Skin and muscle biopsies for case did not show any significant abnormalities or evidence
of storage disease. Muscle analysis for case 6b was suggestive of reduced mitochondrial
abundance with a mild reduction in complex I + III enzyme activity. NGS analysis of
mitochondrial DNA revealed no deletions; however, there were two homoplasmic variants of
uncertain significance; MT-ND1:m.4084G>A; p.Val260Ile) and MT-ND2:m.5095T>C;
p.Ile290Thr) identified as homoplasmic in his twin brother and mother. Negative single gene
testing included; aCGH, POLG1, SCN1A, Fragile X, Smith-Magenis, and Angelman syndrome.
WES (quad) in 2015 identified two likely clinically unrelated variants of uncertain significance
in both probands; a maternally inherited heterozygous VUS was identified in IDH2 (c.439G>C;
p.Val147Leu) and a paternally inherited heterozygous VUS was identified in MYH2
(c.2963T>C; p.Met998Thr). WGS (quad) was completed and revealed the same variants that
were identified by WES. RNA-Seq of the entire blood transcriptome did not identify any
significant changes in transcript levels or splicing patterns in genes believed to be related to the
clinical presentation of this patient.
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Case 7
This was a 29-y-old woman born full term after an uncomplicated pregnancy and
delivery. At six wk of age she presented with nystagmus and suspected blindness. By three y of
age she had an ataxic gait and progressive incoordination. At eight y of age she had a mildly
abnormal EEG showing interhemispheric asymmetry with intermittent right sided slowing
posteriorly and slow background for age. She was diagnosed with retinitis pigmentosa at 15 y of
age and had severe weakness requiring a wheelchair almost full time. Brain MRI at 22 y of age
were suspicious for neurodegeneration with brain iron accumulation (NBIA)/fatty acid
hydroxylase-associated neurodegeneration (FAHN).
Single gene testing was negative for NPC1, SCA1, SCA2, SCA3, SCA6, SCA7, SCA8,
SCA17, CYP7B1, SPG11, SACS, SPG7, SPG15, PNPLA6, SPG20, SPG21, CCT5, and SPG44.
Muscle biopsy of her right triceps revealed a non-specific type 2 atrophy. mtDNA sequencing
and deletion/depletion analysis from muscle was negative. EMG/NCV, ECHO, and ECG were
unremarkable.
In 2014, WES (trio) identified four maternally inherited variants. A single pathogenic
heterozygous variant in USH2A (c.2276G>T; p.Cys759Phe), a likely pathogenic heterozygous
variant in PANK2 (c.1052C>T; p.Ser351Leu), a heterozygous variant of uncertain clinical
significance in WFS1 (c.2453G>A; p.Arg818His), and a heterozygous VUS in candidate gene
ACBD5 (c.925G>T; p.Gly309Ter). Deletion/duplication analysis was negative for PANK2 and
USH2A and no second variant was identified.
WGS (trio) was diagnostic for a newly described peroxisomal disorder associated with
the ACBD5 gene. The results identified the previously found maternally inherited ACBD5 variant
as well as a paternally inherited heterozygous deletion of exon 4 of ABCD5. Recent case reports
suggest that loss of function variants in ACBD5 impair peroxisomal very long chain fatty acid
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metabolism (β – oxidation). (Ferdinandusse et al., 2017, Yagita et al., 2017). Individuals have
been described with retinal dystrophy/rod-cone dystrophy, abnormal eye movements,
developmental delays, spastic paraparesis, hypomyelination, and signal abnormalities in the
brainstem and deep white matter. (Abu-Safieh et al., 2013 Ferdinandusse et al., 2017, Yagita et
al., 2017).
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Case 8
This case is a 31-y-old female with mild intellectual disability, optic atrophy, spasticity,
and dystonia. Visual deficiencies were first noted at three and a half y of age and omnidirectional
nystagmus was noted at 10 y of age, shortly after she was in a motor vehicle accident. At 15 y of
age she continued to have progressive visual deficiencies along with declines in motor function.
She experienced decreased mobility with sore knees, lower back pain, an inability to run, and a
tendency to fall. Neurological examination at 22 y of age confirmed optic atrophy, ataxia,
peripheral neuropathy, generalized weakness, and lower limb spasticity. Multiple repeated urine
organic acid analysis showed a reproducible increase in lactate and pyruvate and significant
increase in 3-methylglutaconic acid.
Investigations included a swallowing study which revealed moderate oropharyngeal
dysphagia. Brain MRI revealed bilateral symmetric abnormal signals. Muscle pathology and
mtDNA sequencing was unremarkable, but metabolic enzyme testing was revealed a mild
reduction in complex I + III. Genetic testing was normal for OPA1, OPA3, ARSA (MLD) and
GALC (Krabbe disease).
WES (trio) was performed in 2015 and was negative. WGS (trio) was negative. RNA-Seq
of the entire blood transcriptome did not identify any significant changes in transcript levels or
splicing patterns in genes believed to be related to the clinical presentation of this patient.

35

Case 9
This is a 30-y-old female who first presented at 18 mo of age with global developmental
delays. Over the ensuing year she developed dysarthria and progressive ataxia. She began using a
wheelchair full-time around 12 y of age due to the progressive ataxia and weakness in her lower
limbs. Coenzyme Q10 (CoQ10) concentration in muscle tissue was found to be low (11.09 ng/g
fresh tissue, N: >15 ng/g fresh tissue) and she was started on supplementation of CoQ10. Brain
MRI at 12 y of age was unremarkable at the time. EMG was suggestive of a pure motor
neuropathy or neuronopathy, suspicious for a Spinal- Muscular Atrophy (SMA)-like condition.
Genetic testing for SMN1, COQ2, PDSS1, PDSS2, CABC1, CACNA1A, SYNE1, and COQ9 was
negative.
In 2016, WES (trio) was not diagnostic but found one paternally inherited variant of
uncertain clinical significance in PLEKHG5 (c.2695G>A; p.Gly899Ser). Pathogenic variants in
PLEKHG5 are associated with autosomal recessive Charcot-Marie-Tooth (CMTRIC) (OMIM:
615376) and distal spinal muscular atrophy type 4 (DSMA4) (OMIM: 611067).
Deletion/duplication analysis of PLEKHG5 was negative; consequently, this was considered to
not likely be pathogenic.
WGS (trio) identified a homozygous VUS in EXOSC8 at c.98G>A; p.Arg33Lys.
Pathogenic variants in EXOSC8 have been associated with autosomal recessive pontocerebellar
hypoplasia, type 1C (OMIM: 616081). This variant was not identified through WES because of
poor read coverage in this area. Based on the patient phenotype a diagnosis of autosomal
recessive pontocerebellar hypoplasia, type 1C was established (OMIM: 616081 ). RNA-Seq of
the entire blood transcriptome did not identify any significant changes in transcript levels or
splicing patterns in genes believed to be related to the clinical presentation of this patient.
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Cases 10a and 10b.
The proband (Case 10a) is a 23-y-old woman with intellectual disability, progressive
ataxia, vision loss, spasticity, dysarthria, and mild proximal weakness. She was born at term to
distantly consanguineous parents of Syrian descent. Parents reported normal milestones until
around five y of age. By eight y of age she had experienced a regression of her fine and gross
motor skills, dysmetria, nystagmus with saccadic eye movements, scanning speech, dysarthria,
and progressive spinocerebellar ataxia and decreased visual acuity. By her late teenage y she was
experiencing progressive dysphagia, severe truncal titubation, worsening bowel and bladder
incontinence, increased tremor, lower limb spasticity, and further declines in balance and
cognition.
Case 10b is the 18-year-old younger brother of Case 10a. He presented with an identical
history of intellectual disability, progressive ataxia, vision loss, spasticity, dysarthria, and mild
proximal weakness. His first symptoms appeared around eight y of age with generalized
weakness. By 10 y of age he was unable to run and a positive Gower’s sign on examination.
Similar to his sister, he developed dysarthria, dysphagia, scanning speech, ataxia with truncal
titubation, saccadic eye movements, brisk reflexes, upgoing toes, and dysmetria. He also had
moderate cognitive impairment and nighttime enuresis. At 18 y of age he was diagnosed with
osteoporosis.
Initial investigations included brain MRIs for both siblings. The MRI of case 10a
revealed white matter changes. An MRI in Syria for case 10b showed signs of leukomalacia in
the periventricular areas. Repeat MRI for case 10b at 18 y of age revealed white matter changes,
mild atrophy and an elevation of choline levels and iron deposition in globus pallidi and bilateral
thalami suggestive of a neurodegenerative disease such as neurodegeneration with brain iron

37

accumulation (NBIA). Other investigations for the siblings, such as EEGs, ECHOs, EGCs,
EMG/NCV, muscle biopsy, measurement of CoQ10 levels in skeletal muscle, mtDNA
sequencing, and metabolic analysis were unremarkable. Genetic testing included; aCGH,
karyotype, NPC1, NPC2, CABC1, Friedrich ataxia, SCA 1, 2 3, 6, 7, 8, and 17, and a hereditary
spastic paraplegia panel.
WES for both siblings (duo) was completed in 2015 and was negative. WGS (quad) was
completed and identified a homozygous deletion of exon 3 of SLC44A1 in both siblings
(Chr8:108,066,751-108,095, 501x0 (GRCh37)). SLC44A1 encodes for choline transporter-like
protein 1. This deletion was predicted to result in a frameshift at amino acid position 90 and
subsequent termination of 18 codons thereafter. Through GeneMatcher (Sobreira et al., 2015) a
number of other individuals with biallelic variants in SLC44A1 have been identified with a
similar childhood-onset neurodegenerative condition with progressive ataxia, dysphagia,
tremors, cognitive decline, dysarthria, and optic atrophy (Fagerberg et al., 2020) . This was
supported by in vitro work investigating choline transporter defects (Taylor, 2019). RNA-Seq of
the entire blood transcriptome did not identify any significant changes in transcript levels or
splicing patterns in genes believed to be related to the clinical presentation of this patient.
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Case 11
This case is a 16-year-old boy who was referred to the neuromuscular clinic with a complex
neurological disorder characterized by severe distal axonal peripheral neuropathy, progressive
dysphagia, global developmental delay, congenital cataracts, glaucoma, corneal dystrophy,
nystagmus, and retinal detachment.
Testing included mtDNA sequencing, electron transport chain enzyme analysis in skeletal
muscle, mass spectrometry and lab quantification of guanidinoacetate and creatine, and
sequencing of CTDP1. Sequencing of POLG in 2008 identified a variant of uncertain
significance (c.2852A>C; p.Tyr951His). The variant was not maternally inherited, and no
paternal sample was available for family studies.
WES (duo) in 2014 identified several variants of uncertain significance, including the same
POLG variant identified previously. In 2012 the same POLG variant had been reported in
another patient with distal myopathy with cachexia (Pitceathly et al., 2012). The POLG variant
was felt to explain part of the proband’s phenotype (e.g. long-standing progressive muscle
wasting and weakness, cataracts, and borderline CK elevation), but was not felt to explain the
entirety of his phenotype. For example, there was no evidence of a large fiber peripheral
neuropathy or ocular findings in the other reported case . Family studies to investigate the other
variants identified by WES were not informative. This included biallelic variants of uncertain
significance in ZNF469 (c.8260C>T; p.His2754Tyr and c.1457G>A; p.Arg486His) (Brittle
cornea syndrome 1, OMIM: 229200), and a maternally inherited variant in DNM2 (c.2228C>T;
p.Pro743Leu) (Centronuclear myopathy 1, OMIM: 160150).
Because the entirety of this patient’s phenotype was not felt to be explained by the POLG
variant, additional genetic testing was pursued. WGS (duo) in 2018 again identified the same
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likely pathogenic heterozygous variant in POLG (c.2852A>C; p.Tyr951Ser). A recent
publication by Castiglioni et al. in 2018 describes an expansion of the POLG phenotype which
matches most of Case 11’s clinical symptoms.
In addition to the POLG variant, WGS also identified the biallelic variants of uncertain
significance in ZNF469 discussed above as well as a heterozygous variant in EPHA2 of unknown
parental origin (c.1457G>A; p.Arg486His). Pathogenic variants in EPHA2 have been associated
with autosomal dominant cataracts type 6, multiple types (OMIM: 116600). It is presently
unclear if the variants in ZNF469 or EPHA2 are playing any role in the complex eye phenotype
of this patient. RNA-Seq of the entire blood transcriptome did not identify any significant
changes in transcript levels or splicing patterns in genes believed to be related to the clinical
presentation of this patient.
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Case 12
The case is a four-year-old girl with global developmental delay, microcephaly, hypotonia,
hypermobility, and focal epilepsy. She was born by C-section at 38 weeks due to breech
positioning and oligohydramnios. Reduced fetal movements were reported during the pregnancy.
She presented at 4 mo of age with failure to thrive and hypotonia. Her head circumference was
39 cm, just below the second percentile and she had a tent-shaped mouth. She was unable to sit
independently at 18 mo of age but could lie prone and push up via arm extension. She was
admitted at 2 y 6 mo for generalized, tonic-clonic status epilepticus with multiple febrile seizures
within a 24-hour period, this was her first recorded occurrence. She had the ability to walk with
the assistance of a walker but could not crawl or walk independently, and her development
plateaued at 3.5 y of age. She is non-verbal and her communication is limited to shaking her
head for “no”.
Initial investigations included an EEG which was mildly abnormal with some bursts of 4 Hz
sharp waves suggestive of propensity for focal seizures in this area. Brain MRI revealed a small
pituitary cystic structure (4.6 mm), periventricular leukomalacia, prominence of supratentorial
CSF space with moderate dilation of supratentorial ventricles and moderate cerebral volume loss
in the parieto-occipital region. Microarray, EMG/NCV, CK, and a congenital muscular
dystrophy panel testing were negative.
WES (trio) was done in 2017 and identified a paternally inherited heterozygous pathogenic
variant in TSEN54 (c.919G>T; p.Ala307Ser). Deletion/duplication analysis of TSEN54 did not
identify a second variant and her MRI was not consistent with pontocerebellar hypoplasia. WGS
(trio) identified the same TSEN54 variant, but no other findings felt to explain her phenotype.
RNA-Seq of the entire blood transcriptome did not identify any significant changes in transcript

41

levels or splicing patterns in genes believed to be related to the clinical presentation of this
patient.
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Case 13
This case is a 6-y-old female born to non-consanguineous parents. At birth, she weighed
5 lbs with microcephaly (measurement not available). She presented with her first seizure at four
mo of age and an EEG at eight mo of age showed modified hypsarrhythmia consistent with
infantile spasms. At five y of age her epilepsy worsened, and she was diagnosed with probable
Lennox-Gastaut syndrome. MRI studies at fifteen mo of age showed microcephaly (HC = 43 cm,
<3rd percentile), marked cerebral atrophy, and high T2 signal in the basal ganglia and
cerebellum. At four y of age she was diagnosed with cortical blindness. Developmental
regression and reduced hearing was noted at five and a half y of age, resulting in the loss of
previously gained abilities including gross and fine motor skills and overall social interaction.
Examination found spasticity and brisk reflexes in all four limbs. Chromosome aCGH was
negative.
In 2014, WES (trio) identified a single heterozygous paternally inherited variant in
RMND1 (c.713A>G; p.Arg238Ser). Pathogenic biallelic variants in RMND1 are associated with
(Combined Oxidative Phosphorylation Deficiency 11 (COXPD11), OMIM: 614922). No second
variant in RMND1 was identified. Also found were two compound heterozygous variants of
uncertain clinical significance in candidate gene TKT (c.133G>A; p.Ala45Thr and c.976C>T;
p.Arg326Cys). Her TKT enzyme activity was reported as 7.3 nmol/mg protein/minute (controls:
12.1—17.8). This activity of TKT in fibroblasts is decreased to approximately 50% of normal,
which was not felt to be sufficient to be disease causing. WGS (trio) identified the previously
reported variants in RMND1 and TKT. No additional variants were identified. RNA-Seq of the
entire blood transcriptome did not identify any significant changes in transcript levels or splicing
patterns in genes believed to be related to the clinical presentation of this patient.

43

Case 14
This case 14 is a 17-y-old woman born to consanguineous parents with intellectual
disability, myoclonus, dystonia, chorea, supranuclear vertical gaze palsy, and dystonia. The
initial onset of her movement disorder was observed at four mo of age and involved her arms,
legs, hands, and tongue. These movements did not involve her face and did not occur in her sleep
but worsened when participating in tasks. Her developmental milestones were globally delayed,
she began to walk at the age of three and demonstrated speech and language delays. Assessment
at age 12 y revealed that she was at a 6-y intellectual level. Her head circumference at this time
was 56.5 cm (>97th percentile). She exhibited a supranuclear gaze palsy, oculomotor apraxia, and
facial myoclonus with dystonia. Her speech articulation was affected by her movement disorder
and vocal cord nodules. Her chorea was slowly progressive, and she reported occasional
episodes of dysphagia when she had increased myoclonus. Nystagmus was noted on physical
examination with slow-moving saccades in the horizontal plane, and she showed an inability to
look downward past the midline. Examination at 17 y of age revealed dystonia in the hands with
rapidly alternating movement and dystonia in her legs and feet. She had significant balance
problems with a slightly broad ataxic gait.
Initial investigations included a brain MRI which showed subtle diffuse periventricular
white matter high signals on T2 weighted images. Urine metabolic screen, urine organic acids,
serum copper, ceruloplasmin, lactate, and plasma amino acids were unremarkable. Molecular
genetic analysis of NPC1, NPC2, and microarray were negative.
WES (trio) was negative. WGS (duo) in 2018 detected a homozygous variant of uncertain
significance in SCN3A (c.2204A>G; p.Asn735Ser). Pathogenic variants in SCN3A have been
associated with an autosomal dominant familial focal epilepsy with variable foci (FFEVF4),
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(OMIM: 604364). Since neither the proband nor either of her parents had a history of epilepsy
this variant was felt to not explain the patient’s phenotype. RNA-Seq of the entire transcriptome
from fibroblasts did not identify any significant changes in transcript levels or splicing patterns
in genes believed to be related to the clinical presentation of this patients.
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Case 15
This case is a 9-y-old boy born at 41.5-wk gestation after a pregnancy complicated by
polyhydramnios and decreased fetal movements. He had bilateral talipes equinovarus requiring
serial casting and tenotomy of the left foot. He was delayed in meeting motor milestones. At age
two he was able to sit with no supports and crawl independently. He was able to pull to stand but
unable to support his full weight when standing. By four y he was able to walk with a walker. He
had reduced fine motor skills due to significant distal weakness in his hands. Feeding was an
issue due to choking spells when consuming fluids without a straw and swallowing studies
revealed thin fluid aspiration and limited penetration without trace aspiration. His speech was
impacted by vocal weakness/hypophonia.
Nerve conduction studies and EMG revealed median and ulnar velocities of
approximately 10 m/s and a diagnosis of congenital hypomyelinating neuropathy was suspected.
Sequencing of EGR2, PRX, ENFL, LITAF, GDAP1, FGD4, FIG4, MTMR2, SH3TC2, NDRG,
PMP22, and MPZ were negative.
In 2014, WES (trio) identified two variants in genes possibly associated with his reported
phenotype. A heterozygous de novo variant at c.23C>T; p.Thr8Met)in SETX and a heterozygous
paternally inherited VUS at c.2176G>A; p.Val726Met in IGHMBP2. Heterozygous pathogenic
variants in SETX have been associated with (juvenile ALS type 4 (OMIM: 602433) while
biallelic pathogenic variants in SETX have been associated with ataxia-oculomotor apraxia type 2
(OMIM: 606002). Clinically it was felt that his phenotype was earlier onset and more severe than
the phenotype described in juvenile ALS Type 4. Biallelic pathogenic variants in IGHMBP2 are
associated with spinal muscular atrophy with respiratory distress type 1 (SMARD1) (OMIM:
604320); however, deletion/duplication analysis of IGHMBP2 was negative and no second
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variant was identified. SETX has a 42% shared homology with IGHMBP2 which also raised the
possibility of a synergistic interaction between the variants identified in these two genes. WGS
(trio) was completed and revealed the same variants identified by WES. No additional variants of
interest were identified. RNA-Seq of the entire blood transcriptome did not identify any
significant changes in transcript levels or splicing patterns in genes believed to be related to the
clinical presentation of this patient.
Since these results have been returned, we have been made aware of a few other cases of
children with the same de novo variant in SETX (c.23C>T; p.Thr8Met) and identical phenotype.
Further work is being done to better characterize and publish this possible expansion in
phenotype.

47

Case 16
This case 16 is a 10-y-old girl born at 37 wk gestation after a pregnancy complicated by
oligohydramnios and reduced fetal movements. She presented at six mo of age due to delays in
meeting her gross and fine motor milestones. She gained the ability to walk independently at two
y of age but continues to use a walker due to difficulty with balance. Evaluation at seven y of age
found truncal hypotonia, intention tremor, balance problems that appeared cerebellar in nature,
and spasticity and weakness in the lower extremities. She had moderate intellectual disability
with roughly 30 words in her vocabulary and would use just two words together at a time. She
was not toilet trained. Bilateral hearing loss was also documented at this time. A brain MRI at 9
y of age showed a complex septate pineal gland cyst and persistent diffuse cerebellar volume
loss prominent in the vermis.
Initial investigations included normal; lactate, ammonia, electrolytes, ALT, AST, CK,
cholesterol, 7-dehydrocholesterol, homocysteine, alpha-fetoprotein, acylcarnitine profile, plasma
amino acids, total and free carnitine, vitamin B12, transferrin isoelectric focusing, and uric acid
levels. Muscle biopsy of the right quadriceps skeletal muscle showed a slight enlargement of
mitochondria with no paracrystalline inclusions. Respiratory chain enzyme activities and
fibroblast studies for pyruvate dehydrogenase complex deficiency and pyruvate carboxylase
activity were unremarkable.
A myopathy panel identified a heterozygous de novo variant of uncertain significance in the
RMND1 gene (c.759dup; p.His254Thrfs*2). Pathogenic variants in this gene have been
associated with autosomal recessive combined oxidative phosphorylation deficiency
(COXPD11) (OMIM: 614922). No second variant was identified. mtDNA sequencing, a
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hereditary spastic paraplegia (HSP) panel, karyotype, microarray, and SCA 1, 2, 3, 6, 7, 8, 17
were all negative.
WES (trio) in 2016 was negative. WGS (trio) identified the same de novo RMND1
variant seen previously as well as a paternally inherited heterozygous likely pathogenic variant in
SLC12A6 (c.2230C>T; p.Arg744Ter). Neither variant was felt to definitively explain the
patient’s phenotype. RNA-Seq of the entire blood transcriptome did not identify any significant
changes in transcript levels or splicing patterns in genes believed to be related to the clinical
presentation of this patient.
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Case 17
This case is a 12-y-old girl born at 39 wk gestation by caesarean section after a pregnancy
was complicated by mild placenta abruption at 27 weeks. Nystagmus was observed at birth and
she was diagnosed with laryngomalacia and gastroesophageal reflux disease (GERD) during the
neonatal period. Her first unprovoked seizure occurred at three mo of age with upward rolling
eyes, full body convulsions, and apnea. EEG showed bifrontal epileptiform charges. Brain MRI
showed delayed myelination and enlarged ventricles with prominent bifrontal extra-axial CSF
spaces with cerebellar atrophy and diffuse volume loss.
She was able to sit independently at three y of age and gained the ability to walk with a
walker by age six y. She has limited fine motor skills and is not able to grasp objects. She is
primarily non-verbal with the exception of “yes” and “no”. aCGH, Rett syndrome, metabolic
screen, and routine bloodwork were unremarkable. She has multiple dysmorphic features such as
a small and smooth philtrum pectus carinatum, high arched palate, bilateral pes planus, 2-3 digit
syndactyly, and bilateral arachnodactyly.
WES (trio) was negative. WGS (trio) revealed two variants of uncertain significance; one
heterozygous maternally inherited variant in RANBP2 (c.5579A>C; p.Lys1860Thr), and a
heterozygous paternally inherited variant in CHRNA2 (c.859_862delinsC;
p.Phe287_Tyr288delinsHis). RNA-Seq of the entire blood transcriptome did not identify any
significant changes in transcript levels or splicing patterns in genes believed to be related to the
clinical presentation of this patient.
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Case 18
This case is a 17-y-old woman with features of both spinocerebellar ataxia (SCA) and
hereditary spastic paraplegia (HSP). She was born at full-term to non-consanguineous parents
after an uncomplicated pregnancy and delivery. She met normal developmental milestones until
8 mo of age when her development stagnated. Developmental regression was noted at age 10 mo
as she was losing her balance and no longer cruising around furniture. By 15 mo she could no
longer crawl or stand and was non-verbal. Her head circumference was 48 cm (>95th percentile).
Brain MRI at 15 y showed mild cerebellar atrophy and VEP was indicative of abnormal visual
evoked responses with slowing. Examination found clonus in both feet, upgoing toes, and
excessive drooling. She eventually re-gained the ability to cruise along furniture, developed a
pincer grasp, could point to objects she was interested in, and use monosyllables. At 15 y of age
her balance was notably better, and she no longer required any gait assisting devices and was
independent for all activities of daily living (ADLs).
Initial investigations included an unremarkable EEG. Lactate, carboxyltransferase,
electrolytes, CBC, TSH, glucose, very long chain fatty acids, cholesterol, triglycerides,
ceruloplasmin, urine organic acids, plasma amino acids, urine purine/pyrimidine profile,
guanidinoacetate, and creatine/creatinine ration were negative.
Muscle pathology on a biopsy of skeletal muscle from the right vastus lateralis was
unremarkable. Mitochondrial respiratory chain enzyme analysis on skeletal muscle revealed a
mild complex I+III deficiency. mtDNA deletion analysis of skeletal muscle tissue and mtDNA
sequencing on cultured fibroblasts were both negative. Genetic testing for Rett syndrome,
GAMT deficiency, Friedreich ataxia, SCA 1, 2, 3, 6, 7, 8, 17, a panel of nuclear genes associated
with mitochondrial disease (N = 406), and aCGH were unremarkable negative.
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WES in 2014 was negative. WGS (trio) identified a few variants of uncertain significance
in genes with autosomal recessive inheritance. One was a paternally inherited heterozygous
likely pathogenic variant in KIAA056 (c.922C>T; p.Gln308Thr). Pathogenic variants in this gene
are associated with autosomal recessive Joubert syndrome 26 (OMIM: 616784). A maternally
inherited heterozygous likely pathogenic splice site variant in PNPT1 (c.1441+2T>A).
Pathogenic variants within this gene are associated with autosomal recessive combined oxidative
phosphorylation deficiency-13 (COXPD13) (OMIM: 614932). A third heterozygous likely
pathogenic variant was seen in SLC39A8 (c.610G>; p.Gly204Cys) and was also of maternal
origin. Pathogenic variants in this gene have been associated with autosomal recessive congenital
disorder of glycosylation type IIn (OMIM: 616721). No second variant was identified in any of
these three genes. RNA-Seq of the entire blood transcriptome did not identify any significant
changes in transcript levels or splicing patterns in genes believed to be related to the clinical
presentation of this patient.
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Case 19
This case is a 49-y-old woman with a complex neurodegenerative disorder and
neuropsychiatric features. Parents report normal development until she experienced a significant
regression with her cognition, speech, and gait after undergoing corrective surgery for scoliosis
at 13 y of age. She required full-time use of a wheelchair by 15 y of age and was dependent on
her parents for all ADL’s. At age 43 y she began to experience visual hallucinations, anxiety, and
behavioural problems such as increased violence.
MRI was suggestive of mitochondrial cytopathy with diffuse cerebral and cerebellar
atrophy, basal ganglia loss, and T2 hyperintensity in the transverse pontine fibers. Increased
choline and decreased N-acetylaspartate (NAA) were observed in basal ganglia. Genetic testing
of NPC1, NPC2, SCA 1, 2, 3, 6, 7, 8, 17, and Friederichs ataxia were all negative. Acylcarnitine
profile, plasma amino acids, serum lactate, urine metabolic screen, and urine organic acids were
unremarkable.
WES in 2014 revealed compound heterozygous variants in trans in VPS13A (c.5884C>T;
p.Arg1962Cys and c.8676C>T, p.Ile289Ile). VPS13A has been associated with autosomal
recessive choreoacanthocytosis (OMIM: 200150), however this diagnosis was felt to not fit her
clinical picture due to an absence of acanthocytes in her blood. WGS (duo) was negative. RNASeq of the entire blood transcriptome did not identify any significant changes in transcript levels
or splicing patterns in genes believed to be related to the clinical presentation of this patient.
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Case 20
This case 20 is a 38-y-old woman with spinocerebellar ataxia, optic atrophy, and
intellectual disability. She exhibited ataxia early in childhood and did not walk independently
until after 18 mo of age. Her ataxia was slowly progressive, and she continues to have difficulties
with ambulation requiring a wheelchair for longer distances. At 24 y of age she was diagnosed
with bilateral optic atrophy and visual evoked potentials were abnormal with no observable
peripheral or central responses. Physical exam found limited downgaze, horizontal nystagmus,
ptosis, oculomotor apraxia, significant intention tremor, mild scanning speech, and truncal
titubation.
Initial investigations included a brain MRI at 14 y which was normal but by 28 y of age
her MRI showed a prominence of the cerebellar fovea, vermis and CSF spaces in the posterior
fossa. Nerve conduction studies showed evidence of a predominantly axonal sensorimotor
polyneuropathy. Biopsy of the right sural nerve revealed axonal neuropathy and demyelination.
Biochemical testing of skeletal muscle revealed normal levels of CoQ10 with a reduction in the
enzyme activity of complex I + III.
Genetic testing included molecular analysis for Friedreich ataxia, SCA 1, 2, 3, 6, 7, 8, 17,
POLG, TWNK, microarray, and mtDNA sequencing in skeletal muscle tissue. Testing of
cerebrospinal fluid found normal glucose, protein, and lactate levels.
WES (singleton) was completed in 2017 and identified a number of variants of uncertain
significance, including compound heterozygous variants (in trans) in candidate gene SLC25A10
(c.G449A; p.R150H and c.C574T; p.P192S). SLC25A10 encodes for a mitochondrial protein
carrier, however no association with human disease had been reported to date.
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In 2018, WGS (trio) highlighted a homozygous likely pathogenic splice site variant in
ACAD9 (c.244+3A>G). Review of WES data showed that this variant was identified but was not
felt to be diagnostic because it was not felt that there was a strong phenotype match. However,
RNA-Seq in blood confirmed that exon splicing was affected by this variant. Pathogenic variants
in ACAD9 are associated with mitochondrial complex I deficiency type 20 (MC1DN20). The
classic phenotype is muscle weakness, hypotonia, cardiomyopathy, liver failure, encephalopathy,
and Reye-like episodes in infancy/childhood. Ataxia is still a rarely reported phenotype of
ACAD9-related mitochondrial complex I deficiency and it’s likely this patient represents a milder
phenotype of this condition.
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